The German Cannabis Market Report

What’s inside

1. Germany is the largest medical cannabis market in Europe, and June 2026 marks a defining moment in its trajectory. Following the implementation of the Medical Cannabis Act (MedCanG) on 1 April 2024, the market has undergone explosive structural expansion — with imports nearly tripling year-on-year, telemedicine driving unprecedented patient access, and a wave of regulatory tightening now poised to reshape competitive dynamics.
2. The German Cannabis Market Report 2026, produced by Prohibition Partners in partnership with Business of Cannabis, delivers a definitive data-led analysis of the country's medical cannabis landscape. Drawing on official BfArM import data, distributor and pharmacy intelligence, and proprietary market-sizing scenarios, this report equips operators, investors, regulators and advisors with the insights needed to navigate Europe's most important — and most contested — cannabis market.
3. From import flow analysis and Canada's market dominance, to dried flower SKU expansion, price compression, and the MedCanG amendment's implications, this report is the most comprehensive single resource on the German medical cannabis market available today. Includes scenario-based market sizing through 2030.

Key findings

• Germany has cemented its position as Europe's largest medical cannabis market, with imports of medical cannabis flower nearly tripling year-on-year following the MedCanG reform.
• Canada remains the dominant supplier, but the published BfArM figures understate its true share — once re-export channels via Portugal are factored in, Canada's effective control of German supply is materially higher than headline numbers suggest.

Frequently asked